Before the pandemic, Taj Pharmaceuticals Ltd. shipped negligible amounts of ivermectin to Russia for veterinary use. But over the past year it’s become a popular product for the Indian generic drug maker: Since July 2020, Taj Pharma has sold $5 million worth of the pills for human use in India and overseas. That’s a bonanza for a small family-owned company with an annual revenue of about $66 million.
Sales of the drug, which is primarily approved to treat diseases caused by parasites in livestock and humans, have surged around the world as anti-vaccine propagandists and others tout it as a ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.